Skip to main content

Penile Traction Therapy (PTT)

Penile traction therapy (PTT) is a non-invasive mechanical treatment that applies controlled longitudinal force to the penis. Its principal evidence base is in Peyronie's disease (curvature improvement, length preservation, and as an adjunct to intralesional therapy), with secondary applications in post-radical-prostatectomy penile rehabilitation, pre- and post-penile-prosthesis length optimization, and cosmetic penile lengthening (penile dysmorphophobia).[1][2]

Mechanism of action​

PTT works through mechanotransduction — the cellular process by which mechanical stimuli are translated into biochemical responses. Continuous longitudinal traction:

  • Increases matrix metalloproteinase (MMP) activity within treated tissue, driving collagen degradation and scar remodeling.[3]
  • Decreases smooth-muscle actin expression and induces re-orientation of collagen fibrils along the direction of applied force.[3]
  • In animal models, decreases TGF-β1 and SMAD 2/3 signaling, with antifibrotic, antiapoptotic, and smooth-muscle-preserving effects.[4]

Devices​

DeviceMechanismDaily durationNotes
RestoreX (PathRight Medical)Rod-based traction with counter-bending30–90 minShortest use time; counter-bend feature for curvature; developed with Mayo Clinic; only device with RCT-level evidence in PD and post-RP rehab.[1][2]
Penimaster PRO (MSP Concept)Vacuum-adhesion + traction3–8 hoursDose-dependent response; vacuum grip avoids strap compression.[5]
Andropenis / Andropeyronie (Andromedical)Strap-based traction4–6 hoursLongest track record; most studied for cosmetic lengthening.[6]
Golden Erect (Ronas Tajhiz Teb)Strap-based traction4–9 hoursLimited data.[7]

Research currently favors Penimaster PRO and RestoreX for Peyronie's disease outcomes.[1]

Clinical indications and evidence​

Peyronie's disease — strongest evidence base​

PTT is recognized by the AUA, EAU, CUA, and ISSM as having a role in PD management, with varying recommendation strength.[3] It can be used as monotherapy or in combination with intralesional injections (CCH, IFN α-2b, verapamil) or surgery.[8]

TrialDevice / ProtocolKey outcome
Ziegelmann 2019 J Urol RCT (n=110, Mayo)[9]RestoreX 30–90 min/day × 3 mo+1.5 cm length, −11.7° curvature, EF improvement (p < 0.001)
Joseph 2020 RestoreX OLE follow-up[10]extended use95% length gains at 6 mo, 61% curvature improvements
Moncada 2019 BJU Int Penimaster PRO RCT (n=93, stable PD)[5]3–8 h/day × 12 wkDose-dependent: > 6 h/d → −38.4° curvature (51.4% improvement), +1.8 cm length; < 4 h/d → no significant benefit
Cochrane 2023 (Rosenberg)[3]SRAcknowledged potential of PTT but flagged high uncertainty due to limited trials and small sample sizes

Post-radical-prostatectomy penile rehabilitation​

Radical prostatectomy commonly causes penile shortening, ED, and corporal fibrosis.[11]

  • Toussi 2021 J Urol RestoreX RCT (n=82): 6 mo PTT → +1.6 cm length preservation vs +0.3 cm controls (p < 0.001), with improved EF and patient satisfaction.[12]

Pre- and post-penile-prosthesis length optimization​

PTT has been used to optimize penile length before IPP placement, particularly in men with shortening from prior surgery, explantation, or PD.[13][14]

  • Levine 2011 pilot (n=10, 2–4 h/day × 2–4 mo before IPP): no measured or perceived length loss post-implant; 70% achieved a small erect length gain (up to 1.5 cm).[14]
  • Moskovic 2011 case report: 8 mo post-prosthesis PTT → +2.3 cm stretched penile length, enabling revision with a 20% longer device (15 cm → 18 cm).[15]
  • Evidence in this indication remains very limited.[1]

Cosmetic / aesthetic penile lengthening (penile dysmorphophobia)​

Most men seeking penile enhancement have normal dimensions and either suffer from penile dysmorphophobia or are misinformed about normal size.[6]

  • AndroPenis (Nowroozi 2015): n=54 with penile dysmorphophobia, 4–6 h/day × 6 mo → +1.7 cm flaccid, +1.3 cm stretched, +1.2 cm erect (all p < 0.001).[6]
  • Golden Erect (Nikoobakht 2011): n=23, 4–6 h/day initially, then 9 h/day × 3 mo → flaccid 8.8 → 10.5 cm; stretched 11.5 → 13.2 cm (p < 0.001).[7]
  • Oderda-Gontero 2011 SR: penile extenders are the only evidence-based non-surgical technique for penile elongation; results not inferior to surgical lengthening phalloplasty.[16]
  • Romero-Otero 2021 SR (BJU Int): PTT confirmed as the only evidence-based non-surgical lengthening intervention; overall study quality remains low.[17]
  • Structured psychosexual counseling should precede any intervention in men with cosmetic concerns — many can be reassured without treatment.[6] See Small Penis Syndrome / PDD and Cosmetic Genital Surgery.

Combination therapy​

PTT can be combined with intralesional injections or as adjunct to surgical correction of PD.[8]

CCH + RestoreX — best documented non-surgical combination​

The Alom 2019 J Sex Med three-arm comparison is the central evidence anchor:[19]

OutcomeCCH alone (n=38)CCH + other PTT (n=32)CCH + RestoreX (n=43)
Curvature improvement20.3° (31%)19.2° (30%)33.8° (49%)
Length change−0.7 cm (−4%)−0.4 cm (−2%)+1.9 cm (+17%)
Subjective curvature improvement44%32%63%
Daily PTT use—1.9 h0.9 h
≥ 20° curvature improvementreferenceNS vs CCH aloneOR 6.9
≥ 50% curvature improvementreferenceNS vs CCH aloneOR 3.5
≥ 20% length improvementreferenceNS vs CCH aloneOR 10.7

Key takeaways. CCH + RestoreX enhanced curvature outcomes by 71% and converted length loss to length gain vs CCH alone. CCH + other PTT devices showed no benefit over CCH alone — even in patients using other devices ≥ 3 h/day. RestoreX achieved superior results with less than half the daily use time (0.9 vs 1.9 h). AEs were similar across arms.[19] The Cahill 2025 826-patient multivariate analysis confirmed RestoreX use as the factor associated with the largest curvature improvement of any predictor assessed (5–20° depending on test).[20]

The Ziegelmann 2017 Urology "true-to-life" experience with the Andropenis device (n = 51) — in contrast to the RestoreX data — showed mean curvature improvement of 20.9°, similar to CCH alone, reinforcing that device design matters.[21]

CCH + PTT (IMPRESS-extension protocol — García-Gómez 2021)​

Prospective multicenter single-arm study (n = 87) using IMPRESS protocol + a penile extender ≥ 4 h/day starting 24–48 h after injection — mean curvature 57° → 34° (−23.3°, −41%) achieved with a mean of only 2 cycles (vs 4 in IMPRESS).[22]

CCH + IFN α-2b combinations​

  • Yafi 2015 J Urol: when combined with interferon α-2b, PTT ≥ 3 h/day provided a small but significant additional stretched penile length gain (+ 4.4 mm vs + 1.3 mm, p = 0.04).[18]

Emerging "3 Ts" multimodal protocol (Hatzichristou 2026)​

A paradigm-shift framework: Tadalafil daily (improves cavernosal oxygenation, counteracts hypoxia-driven fibrosis) + Tunneling with intralesional biologics (delivers growth factors directly into/around the plaque) + Traction therapy daily (mechanotransductive realignment) — reframing PD management from "deformity correction" to "structural restoration." Prospective randomized validation pending.[23]

Treatment protocols​

No universally standardized protocol exists.[11][8] General principles:

  • Duration: ranges from 30 min/day (RestoreX) to 3–8+ hours/day (traditional devices). Longer daily use correlates with greater curvature and length improvement in a dose-dependent manner.[5][18]
  • Treatment course: typically 3–6 months minimum; continued use beyond 3 months yields additional length gains.[10]
  • Force: progressive increase per device-specific instructions.

Safety​

PTT is consistently reported as safe and well-tolerated across all indications.[9][8][5][6]

  • Adverse events are transient and mild — erythema, local discomfort, skin irritation, temporary glans numbness — typically resolving within minutes of device removal.[10]
  • No serious adverse events (penile fracture, permanent numbness, vascular compromise) reported in published trials.
  • RestoreX PD trial: 87% would repeat therapy, 93% would recommend.[12]
  • Mild AEs in ~ 43% of Penimaster PRO users (discomfort, glans numbness).[5]

Limitations​

  • Compliance is the single greatest barrier — daily use for extended periods is demanding, and adherence is highly variable.[1][11]
  • No standardized protocols across devices and indications.[8]
  • No effect on penile girth has been consistently demonstrated.[6][7]
  • Limited long-term data — most studies report at 3–9 months; durability beyond is uncertain.[10]
  • Overall quality of evidence is low, with small samples and heterogeneous designs.[3][17]
  • Cost and availability vary regionally; not typically covered by insurance.[1]

Guideline positioning​

The AUA, EAU, CUA, and ISSM all acknowledge a role for PTT in Peyronie's disease management with varying levels of endorsement.[3] The 2015 ICSM consensus concluded PTT is "a viable therapy to modestly improve penile length" as primary therapy, before prosthesis placement, or after PD surgery, with possible role in acute-phase PD but inconsistent outcomes in chronic disease.[2] For cosmetic lengthening, PTT is positioned as the only evidence-based non-surgical option, though robust recommendations are lacking due to low-quality evidence.[16]

See also​

Peyronie's Disease (Male Sexual Dysfunction atlas) · Peyronie's Disease Agents (pharmacology) · Penile Implants · Small Penis Syndrome / PDD · Cosmetic Genital Surgery

References​

1. Sultana A, Grice P, Vukina J, Pearce I, Modgil V. Indications and characteristics of penile traction and vacuum erection devices. Nat Rev Urol. 2022;19(2):84-100. doi:10.1038/s41585-021-00532-7

2. Trost LW, Munarriz R, Wang R, Morey A, Levine L. External mechanical devices and vascular surgery for erectile dysfunction. J Sex Med. 2016;13(11):1579-1617. doi:10.1016/j.jsxm.2016.09.008

3. Rosenberg JE, Ergun O, Hwang EC, et al. Non-surgical therapies for Peyronie's disease. Cochrane Database Syst Rev. 2023;7:CD012206. doi:10.1002/14651858.CD012206.pub2

4. Lin H, Liu C, Wang R. Effect of penile traction and vacuum erectile device for Peyronie's disease in an animal model. J Sex Med. 2017;14(10):1270-1276. doi:10.1016/j.jsxm.2017.08.011

5. Moncada I, Krishnappa P, Romero J, et al. Penile traction therapy with the new device 'Penimaster PRO' is effective and safe in the stable phase of Peyronie's disease: a controlled multicentre study. BJU Int. 2019;123(4):694-702. doi:10.1111/bju.14602

6. Nowroozi MR, Amini E, Ayati M, et al. Applying extender devices in patients with penile dysmorphophobia: assessment of tolerability, efficacy, and impact on erectile function. J Sex Med. 2015;12(5):1242-1247. doi:10.1111/jsm.12870

7. Nikoobakht M, Shahnazari A, Rezaeidanesh M, Mehrsai A, Pourmand G. Effect of penile-extender device in increasing penile size in men with shortened penis: preliminary results. J Sex Med. 2011;8(11):3188-3192. doi:10.1111/j.1743-6109.2009.01662.x

8. Bole R, White L, Parikh N, et al. A modern review of penile traction monotherapy and combination therapy for the treatment of Peyronie's disease. Int J Impot Res. 2021;33(3):251-258. doi:10.1038/s41443-020-0247-3

9. Ziegelmann M, Savage J, Toussi A, et al. Outcomes of a novel penile traction device in men with Peyronie's disease: a randomized, single-blind, controlled trial. J Urol. 2019;202(3):599-610. doi:10.1097/JU.0000000000000245

10. Joseph J, Ziegelmann MJ, Alom M, et al. Outcomes of RestoreX penile traction therapy in men with Peyronie's disease: results from open-label and follow-up phases. J Sex Med. 2020;17(12):2462-2471. doi:10.1016/j.jsxm.2020.10.003

11. Shu T, Ren D, Wang R. The role of vacuum erection device and penile traction therapy in the patients after radical prostatectomy: a narrative review. Int J Impot Res. 2025. doi:10.1038/s41443-025-01092-9

12. Toussi A, Ziegelmann M, Yang D, et al. Efficacy of a novel penile traction device in improving penile length and erectile function post-prostatectomy: results from a single-center randomized, controlled trial. J Urol. 2021;206(2):416-426. doi:10.1097/JU.0000000000001792

13. Krishnappa P, Matippa P, Fraile-Poblador A, Lledo-Garcia E, Moncada I. Penile length preservation in penile prosthesis placement: tips & tricks. Int J Impot Res. 2025. doi:10.1038/s41443-025-01123-5

14. Levine LA, Rybak J. Traction therapy for men with shortened penis prior to penile prosthesis implantation: a pilot study. J Sex Med. 2011;8(7):2112-2117. doi:10.1111/j.1743-6109.2011.02285.x

15. Moskovic DJ, Pastuszak AW, Lipshultz LI, Khera M. Revision of penile prosthesis surgery after use of penile traction therapy to increase erect penile length: case report and review of the literature. J Sex Med. 2011;8(2):607-611. doi:10.1111/j.1743-6109.2010.02121.x

16. Oderda M, Gontero P. Non-invasive methods of penile lengthening: fact or fiction? BJU Int. 2011;107(8):1278-1282. doi:10.1111/j.1464-410X.2010.09647.x

17. Romero-Otero J, Manfredi C, Ralph D, et al. Non-invasive and surgical penile enhancement interventions for aesthetic or therapeutic purposes: a systematic review. BJU Int. 2021;127(3):269-291. doi:10.1111/bju.15145

18. Yafi FA, Pinsky MR, Stewart C, et al. The effect of duration of penile traction therapy in patients undergoing intralesional injection therapy for Peyronie's disease. J Urol. 2015;194(3):754-758. doi:10.1016/j.juro.2015.03.092

19. Alom M, Sharma KL, Toussi A, Kohler T, Trost L. Efficacy of combined collagenase clostridium histolyticum and RestoreX penile traction therapy in men with Peyronie's disease. J Sex Med. 2019;16(6):891–900. doi:10.1016/j.jsxm.2019.03.007

20. Cahill EM, Trost L. Factors associated with improved curvature outcomes with collagenase clostridium histolyticum for Peyronie's disease: results from a large prospective series. J Sex Med. 2025;qdaf213. doi:10.1093/jsxmed/qdaf213

21. Ziegelmann MJ, Viers BR, Montgomery BD, et al. Clinical experience with penile traction therapy among men undergoing collagenase clostridium histolyticum for Peyronie disease. Urology. 2017;104:102–109. doi:10.1016/j.urology.2017.01.054

22. García-Gómez B, García-Rojo E, Alonso-Isa M, et al. Treatment of Peyronie's disease with combination of clostridium histolyticum collagenase and penile traction therapy: a prospective, multicenter, single-arm study. Int J Impot Res. 2021;33(3):325–331. doi:10.1038/s41443-020-0292-y

23. Hatzichristou D. From fibrosis to restoration: the multimodal 3 Ts protocol for Peyronie's disease. Int J Impot Res. 2026. doi:10.1038/s41443-026-01262-3